Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

Mayo Clinic and Foundation, Rochester MN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Rochester MN
Treatments:ChemotherapyHospital:Mayo Clinic and Foundation
Drugs:Journal:Link
Date:Feb 2006

Description:

Patients: This Phase II study involved 59 women with metastatic breast cancer. The median age was 51 years. Three patients were African-American, one was Asian, and the rest were Caucasian. Most (54) received prior adjuvant therapy, while 36 had received prior chemotherapy for metastatic disease. Twenty-eight received hornomal therapy before treatment.

Treatment: The treatment consisted of two chemotherapeutic agents: pemetrexed and gemcitabine.

Toxicity: Grade 3-4 toxicities included neutropenia, leukopenia, thrombocytopenia, fatigue, dyspnea, skin rash, and anorexia.

Results: The median overall survival was 10.3 months. Fourteen patients had a partial response, and nine patients had stable disease.

Support: Eli Lilly and Company provided financial support for this study. Eli Lilly manufactures and/or markets gemcitabine and pemetrexed.

Correspondence: Dr A. A. Adjei




Back